Precigen, Inc. · NASDAQ:PGEN
Precigen — Intrexon — Corporate Update (December 2018)
15 slides from Precigen's corporate update, Dec 26, 2018
Slide 1: Precigen Business Update
Precigen Business Update Helen Sabzevari, PhD President, Precigen 26 December 2018 Exhibit 99.1
Slide 2: Forward-looking statements
Forward-looking statements
Slide 3: Today's business updates
Today’s business updates Introduction to Precigen’s near-term R&D strategies Precigen’s transformation to an agile R&D engine Agreement overviews for Ziopharm and Merck KGaA Introduction to Precigen’s transformative platform technologies, including UltraCAR-TTM An overview of the opportunity in immu
Slide 4: Near-term R&D strategy sets up company for long-term success
Transition from exclusive channel collaboration (ECC) to in-house agile R&D model Regain full developmental control of therapeutics for rapid execution of programs Focus pipeline assets to core TAs Limit therapeutic focus to TAs with highest opportunity and unmet need Build rapid discovery to develo
Slide 5: Ziopharm license agreement returns rights to pursue CAR targets
Ziopharm license agreement returns rights to pursue CAR targets Agreement Overview Executed October 9, 2018 Replaced existing agreements with Ziopharm Outcome: Precigen has exclusive rights to pursue all CAR targets and Sleeping Beauty system in all tumor types (hematological and solid) subject to:
Slide 6: Merck KGaA 2018 agreement assigns exclusive CAR-T development rights to Intrexon
Merck KGaA 2018 agreement assigns exclusive CAR-T development rights to Intrexon, providing Precigen with complete autonomy of its UltraCAR-TTM platform Agreement Overview Expected to close this year Assigns and transfers all Merck KGaA CAR-T rights to Intrexon Outcome: Assigns Merck KGaA’s exclusiv
Slide 7: Transition from ECC model to agile R&D engine for full control of therapeutics
Precigen has transitioned from an exclusive channel collaboration (ECC) model to agile R&D engine for full control of therapeutics Precigen has full control of oncology portfolio Agreement with Ziopharm CAR-T Cells Cancer Vaccines Cytokine Therapies TCR-T Cells Multifunctional Therapeutics Agreement
Slide 8: Current immunotherapy landscape has promise, but many drawbacks
Current immunotherapy landscape has promise, but many drawbacks CONFIDENTIAL Despite the success, only a minority of patients respond; in some indications there is no response Relapse rates are high among responders to checkpoint inhibitors Combination trials with checkpoint inhibitors have yielded
Slide 9: Platform technologies to control, construct and deliver gene and cell therapies
Precigen’s platform technologies enable success through our ability to control, construct and deliver targeted gene and cell therapies RheoSwitch®: First clinically validated transcriptional gene switch Kill switches: Targeted depletion of cell therapeutics for improved safety profile Tissue specifi
Slide 10: Disrupting the market: UltraCAR-T platform
2. Electroporation 1. Leukapheresis 3. UltraCAR-T Infusion Disrupting the market: Precigen’s transformative UltraCAR-T™ platform Less than two days UltraCAR-T advancements Precigen UltraCAR-T Platform enables patient reinfusion within two days following non-viral gene transfer Leukapheresis and T ce
Slide 11: PRGN-3006 UltraCAR-T received FDA IND clearance for Phase 1/1b
PRGN-3006 UltraCAR-T™, a first-in-class therapy in AML, received FDA clearance for IND to initiate Phase 1/1b study Highlights and Differentiation Autologous T cell investigational therapy Non-viral Sleeping Beauty system to co-express CAR, mbIL15 and kill switch Rapid manufacturing No ex vivo propa
Slide 12: PRGN-3006 UltraCAR-T cells eliminated aggressive AML tumor in mouse model
PRGN-3006 UltraCAR-TTM cells eliminated aggressive AML tumor in an in vivo mouse model PRGN-3006 UltraCAR-T cells administered in less than 2 days after gene transfer expand in vivo and persist in AML tumor bearing mice PRGN-3006 UltraCAR-T cells effectively eliminated AML tumor in mice in dose depe
Slide 13: PRGN-3006 targets AML and MDS; significant unmet need
PRGN-3006 UltraCAR-TTM targets AML and MDS; patient populations with significant unmet need Acute Myeloid Leukemia (AML) Patient Characteristics and Incidence ~20,000 new cases in US in 2018, mostly in adults1 Among most common types of leukemia in adults1 Uncommon before age 451 Average age of diag
Slide 14: Precigen is on track to achieve near-term strategies
Transition from exclusive channel collaboration (ECC) to in-house agile R&D model Regain full developmental control of therapeutics for rapid execution of programs Focus pipeline assets to core TAs Limit therapeutic focus to TAs with highest opportunity and unmet need Build rapid discovery to develo
Slide 15: Precigen
G PRECIGEN ADVANCING MEDICINE WITH PRECISION™ We Ga my